Eli Lilly reports significant weight loss with experimental obesity drug
The company says its investigational candidate drove substantial reductions in body weight, adding to its incretin pipeline data.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 10 12:56 ETSource: BusinessWorld Online
The wire
- 01Eli Lilly reported that an experimental weight-loss drug produced significant reductions in body weight in trial participants.
- 02Lilly's incretin pipeline shapes supply, pricing and prescribing expectations for clinicians and operators already managing semaglutide and tirzepatide patients.
- 03Detailed endpoint figures, dosing and safety data were not provided in the report; full results would be needed to judge the magnitude of effect.
From the source
Read at bworldonline.comeli lilly reports experimental drug drives significant weight loss results
